- Company Name
- Modalis Therapeutics Corporation
- January 2016
- Representative Directors
- Haru Morita
- 3-11-5 Nihonbashi-Honcho, Nihonbashi-Lifescience-Bldg.2 7F Chuo-ku, Tokyo,103-0023 JAPAN
- U.S. Office R&D Operations
- Modalis Therapeutics Inc.
（43 Foundry Avenue, Waltham, Massachusetts, 02453 USA）
※ The research laboratory of Modalis has relocated as of October 20, 2021.
- Scope of Business
- Drug development
- Number of Employees
27 (as of December 31, 2021, consolidated)
Modalis (pronounced “MO-DA-LIS”) is an original name that the Company has chosen to hope Company’s proprietary gene modulation technology, CRISPR-GNDM, to be a new modality (therapeutic technology) to assist patients fighting with genetic disorders. It is the key to treatment of genetic diseases, and the logo of the company name expresses “a gene switch” becoming the target of the CRISPR-GNDM®︎ technology.